Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. ESMO … Receive information and updates on ESMO’s scientific and educational resources, events, members activities. Abstract No : Presentation 910O. Kalyankrishna S, Grandis JR, Epidermal growth factor receptor biology in head and neck cancer, J Clin Oncol, 2006;24:2666–72. List of abbreviations: COVID-19, severe acute respiratory syndrome coronavirus 2-related disease; CT, computed tomography; HPV, human papillomavirus; IO, immuno-oncology; qXw, every X weeks. ESMO Head and Neck Cancer. National Comprehensive Cancer Network. Prof Psyrri is Chair of the Scientific Committee Head and Neck Cancer for the ESMO 2016 Congress, and in 2015 she was ESMO Chair at the International Conference on Innovative Approaches in Head and Neck Oncology in Nice, France and Co-Chair of the Scientific Committee Head and Neck … We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials. New therapeutic strategies for the treatment of nasopharyngeal cancer and squamous cell carcinoma of the head and neck, malignancies associated with poor survival outcomes, were presented at the first European Society for Medical Oncology (ESMO) Asia Congress, held in Singapore in December 2015. To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive. Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: An ASTRO-ESTRO Consensus Statement. This site uses cookies. bleeding, see also under “Priorities for symptomatic recurrent/metastatic patients), Adjuvant radiotherapy for minor risk factors, Multidisciplinary team meetings -physically or virtually- should remain the place where clinical choices about curative treatments are defined, Curative intended radiotherapy should not be postponed for an interval longer than 4-6 weeks, Do not necessarily change fractionation unless radiation-therapy resources are limited, Consider implementing moderately hypofractionated regimens, only in case of extreme shortness of resources (fractions of 2.2-3 Gy), Concurrent chemoradiotherapy should be preferred to induction chemotherapy followed by (chemo)radiotherapy for organ preservation, to limit overall treatment time and chemotherapy-related immunosuppression, High-dose three-weekly cisplatin should be preferred to low-dose weekly cisplatin to reduce medical visits, Consider omitting concomitant chemotherapy only in case of extreme shortness of resources, If the patient tested positive for COVID-19 before treatment, postpone radiotherapy initiation until test becomes negative, Keep continuity in radiotherapy in case of COVID-19 positivity with mild/no symptoms; continue  radiotherapy if at least 2 weeks of treatment have been performed, provided it is clinically practicable, Interrupt treatment in case of severe symptoms. Testing and Targeting Tumours with RET Alterations, Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape, Translating Immunity to Clinical Applications of Immunotherapy in Breast Cancer, Past ESMO Partnership, Labelled and Supported Meetings, ESMO Clinical Research Observatory Task Force (ECRO), Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Asia Virtual Congress 2020, Europe’s Beating Cancer Plan – in 60 minutes. September 17, 2020. Hanna TP, Evans GA, Booth CM. Will Recent Major Trials With CDK Inhibitors Be Practice Changing In Early Breast Cancer? Testing and Targeting Tumours with RET Alterations, Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape, Translating Immunity to Clinical Applications of Immunotherapy in Breast Cancer, Past ESMO Partnership, Labelled and Supported Meetings, ESMO Clinical Research Observatory Task Force (ECRO), Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Asia Virtual Congress 2020, Europe’s Beating Cancer Plan – in 60 minutes. nat. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. PracticeUpdate Editorial Team EPIC-OPC study: misclassification of OPC patients. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Nederlandse Vereniging voor Medische Oncologie Postbus 20066 3502 LB Utrecht tel. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. All funding for this site is provided directly by ESMO. Jean Bourhis, ESMO 2019 – Debio 1143 in head and neck cancer Published Online: October 11th 2019 We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy. National Comprehensive Cancer Network. MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23, The tiered approach of ESMO in delivering a guidance for cancer patients during the COVID-19 pandemic is designed across three levels of priorities, namely: tier 1 (high priority intervention), 2 (medium priority) and 3 (low priority) – defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), incorporating the information on the value-based prioritisation and clinical cogency of the interventions. For more detailed information on the cookies we use, please check our Privacy Policy. Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid.. 3. This program was chaired by the leading experts in the field -Dr. Anthony Chan from Hong Kong and Dr. Jean-Pascal… Would You Like to Join the Young Oncologists Committee? ESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancer Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial. Via Ginevra 4, 6900 Lugano - CH© Copyright 2020 European Society for Medical Oncology All rights reserved worldwide. Supportive care during radiotherapy with/without systemic therapy: Consider replacing weekly on-site patient reviews with video- or telephone-consultations, Early initiation of systemic therapy in patients with fast disease pace, high tumour burden and/or symptomatic, Initiation of systemic therapy in patients with less aggressive disease features, Monotherapy (e.g. Sacha Rothschild. Virtual. Dr. Burtness: The design of JAVELIN Head and Neck 100 was pretty straightforward. risk of fracture or bleeding, Irradiation of symptomatic metastases (depending on symptoms and availability of radiotherapy resources): e.g. Necessary cookies enable core functionality. ESMO is a Swiss-registered not-for-profit organisation. ESMO 2018: Immunotherapy improves survival in metastatic or recurrent head and neck cancer 22 Oct 2018 Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich. The trial was stopped due to futility as Avelumab (A) plus chemoradiotherapy (CRT) followed by avelumab maintenance did not significantly improve PFS when compared to Placebo + CRT followed by placebo maintenance. “Despite today’s current standard of care, high-risk locally-advanced head and neck cancer remains an area of unmet medical need. Would You Like to Join the Young Oncologists Committee? 1x 8 Gy, “QUAD-SHOT”). Head and neck cancer updates presented at ESMO 2020. Patients were treated for locally-advanced head and neck … Via Ginevra 4, 6900 Lugano - CH© Copyright 2020 European Society for Medical Oncology All rights reserved worldwide. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Will Recent Major Trials With CDK Inhibitors Be Practice Changing In Early Breast Cancer? 5:v184–6. 11 - 12 Dec 2020. The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. ESMO 2020: Pembrolizumab Fails to Offer Benefits Over Cetuximab When Combined With Radiotherapy for Advanced Head and Neck Cancer. This Breakthrough Therapy Designation will allow us to maximize the potential of Debio 1143 to become an innovative radio-chemo … Disclaimer. Last weekend (April 13-14, 2019), I was very fortunate to have had the opportunity of participating at the European Society of Medical Oncology (ESMO) Head and Neck Cancer Preceptorship Programme held at Kowloon, Hong Kong. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. At ESMO this year we heard the results of JAVELIN Head and Neck 100 presented by Ezra Cohen from UCSD. Meeting Coverage > ESMO Neoadjuvant IO Yields Deep Responses in Head and Neck Cancer — One-third of patients achieved "near" pCR in phase I/II trial Nat Rev Clin Oncol 2020; 17:268–270. Conferences It has become the norm for late-breaking studies highlighted at major medical meetings’ press conferences to be described as “practice-changing”, and at Esmo today this accolade was bestowed on Merck & Co’s Keynote-048 trial of Keytruda in first-line head and neck cancer. Dr. phil. 4. 24 sep 2021 - 25 sep 2021 ESMO Virtual Preceptorship on Head and Neck Cancer 2021 Online . During the webinar, we will elaborate special considerations for management of head and neck cancer according to the recent ESMO COVID-19 recommendations, as well as head and neck cancer surgery, radiation therapy and systemic palliative treatment in time of COVID-19, illustrated with clinical case presentations and followed by a round table discussion. Educate. Gregoire V, Lefebvre JL, Licitra L, Felip E, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2010;21 Suppl. PracticeUpdate: How was this trial designed? Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. View More Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & … Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Nat Rev Clin Oncol 2020; 17:268–270. bleeding, superior cava syndrome, Irradiation of asymptomatic and non-threatening metastases, Local ablative treatment (surgery/stereotactic radiotherapy) of metastases in oligometastatic setting, Steroids should be avoided as much as possible or administered as conservatively as possible, Consider implementing 1-4 fraction regimens for symptomatic palliative cases (e.g. Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress. Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC. Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE … Indication : Head & Neck Cancer. Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community. ESMO is a Swiss-registered not-for-profit organisation. These guidelines on Squamous cell carcinoma of the head and neck and Nasopharyngeal cancer include information on: incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up. ESMO management and treatment adapted recommendations in the COVID-19 era: Head and Neck Cancers, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, Cancer Patient Management During the COVID-19 Pandemic, COVID-19 and cancer care in the ESMO journals, From ESMO Vision 2020 to ESMO Vision 2025, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Translational Research and Precision Medicine Working Group, Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group. ESMO 2019 Highlights in locally advanced head and neck cancer: A GORTEC Study 01 Oct 2019 ESMO Expert Video Report on Immunotherapy for Head and Neck Cancer Int J Radiat Oncol Biol Phys 2020;107:618-627. In Press. ESMO management and treatment adapted recommendations in the COVID-19 era: Head and Neck Cancers. JAVELIN HEAD AND NECK 100 results at ESMO 2020. Receive information and updates on ESMO’s scientific and educational resources, events, members activities. Available at: https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak (1st September 2020, date last accessed). IARC World Cancer Report Updates Learning Platform and Webinars, ESMO Public Policy Track and Special Sessions, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Gynaecological Cancers Virtual Congress 2021, Molecular Analysis for Precision Oncology Congress 2021, European Lung Cancer Virtual Congress 2021, ESMO Immuno-Oncology Virtual Congress 2020. There have been a number of large trials that have completed accrual, and that we have been waiting for the results of. A study based on programmed cell death-ligand 1 status is currently underway. MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23. Available at: https://www.nccn.org/covid-19/ (26th August 2020, date last accessed). Risk factors for Head and Neck cancer Age Tobacco and alcohol p53 mutation HPV. Intervention : Avelumab + ChemoRT. ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial Her mentor for this presentation was PD Dr. med. Monitor. NVMO. The presence of human papillomavirus p16 alone is not sufficient to classify oropharyngeal cancer (OPC) as HPV-positive, 1 therefore, it is important to define the proportion, determinants, and prognosis of OPC patients who are p16 positive but HPV DNA–negative (p16+/HPV-). To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive. World Health Organization. Company : Pfizer. ESMO Virtual Preceptorship on Head and Neck Cancer 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (26th August 2020, date last accessed). JAVELIN Head and Neck 100 is the first randomized, phase 3 study of an immune checkpoint inhibitor combined with CRT in any tumor type. GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) | GSK 2008 May;19(5):1027-9. COVID-19: Operational guidance for maintaining essential health services during an outbreak. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences. ESMO Virtual Preceptorship on Head and Neck Cancer 2020. Although the 19% improvement in overall survival among patients treated with … SCC (90%) What is the preferred imaging study in HNSCC? meer informatie. In a phase 3 trial, the med only extended second-line head and neck cancer patients’ lives by 8.4 months, compared with the 7.1 months achieved with standard treatment. Cancer patient prioritisation. This site uses cookies. MRI (except laryngeal and hypopharyngeal cancers) In this presentation, Angela Fischer Maranta, KSGR, Chur covers the most important findings from the ESMO virtual meeting 2020 for the topic Head and Neck. Scientific investigation is extremely active in the treatment, management, and optimization of therapies for patients with head and neck cancer. capecitabine), when feasible, might be offered to avoid frequent access to hospital, Tracheotomy in case of obstruction of the upper airways/stridor, Threatening lesion, e.g. Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO-ESO Courses on Medical Oncology for Medical Students, SARS-CoV-2 Vaccination: Special Considerations in Patients with Cancer, ESMO Guidelines: Real World Cases - Live Webinars. ESMO Guidelines Working Group, Pivot X, Villanueva C. Erratum in Ann Oncol. Monitor. NCCN Guidelines Head and Neck Cancers Version 2.2020. These issues have undergone recent rapid evolution in response to a changing epidemiology based on an increasing proportion of HPV-associated oropharyngeal cancer with advances in multimodality technologies to improve outcomes and reduce toxicity. IARC World Cancer Report Updates Learning Platform and Webinars, ESMO Public Policy Track and Special Sessions, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Gynaecological Cancers Virtual Congress 2021, Molecular Analysis for Precision Oncology Congress 2021, European Lung Cancer Virtual Congress 2021, ESMO Immuno-Oncology Virtual Congress 2020, https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak, https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf, Gastrointestinal cancers: Colorectal cancer (CRC) in the COVID-19 era, Gastrointestinal cancers: Gastro-oesophageal tumours in the COVID-19 era, Gastrointestinal cancers: Pancreatic cancer in the COVID-19 era, Gynaecological malignancies: Epithelial ovarian cancer in the COVID-19 era, Patients experiencing acute toxicities during curative treatment with radiation/systemic therapies, Post-operative patients with complications, Head and neck cancer survivors experiencing signs/symptoms of recurrence, Head and neck cancer survivors experiencing late toxicities, Post-operative or post-(chemo)radiotherapy patients with no complications, Psychological support visits (convert to telemedicine), Patients in early follow-up (first 2 years) after curative treatment, Patients in late follow-up (after 2 years) with neither signs/symptoms of recurrence nor toxicities: refer to telemedicine and postpone imaging, Visits between two treatments for patients on systemic palliative treatment: refer to telemedicine, Prior to any in-person visit, patients should be screened for symptoms of COVID-19 by maximising telemedicine triage and establishing screening at intake by using checklists and monitoring tools, Telemedicine may play a role in primary assessment of signs and symptoms, reassuring anxious subjects, while prompting an urgent in-person visit in case of doubts (new lump in the neck, dysphagia, dyspnoea, minor bleeding…), However, clinical examination of the head and neck via telemedicine for oncological reasons should be avoided except for a general inspection of the neck, face and anterior oral cavity (also in such circumstances, however, it should be noted that palpation and close inspection are the main resources for clinical judgement, especially in already treated patients), Larynx – Hypopharynx: cT3-cT4, every cTN+, rT3-rT4, every rTN+, every patient with instable airway (dyspnoea or pending dyspnoea, dysphagia, painful swallowing, risk of bleeding…), Oral cavity – Oropharynx: cT2-cT4, every cTN+, every patient with instable airway (dyspnoea or pending dyspnoea, dysphagia, painful swallowing, risk of bleeding…), pathological fracture of the mandible, trismus, Paranasal sinuses: cT2-cT4, every cTN+, every patient with diplopia, facial deformity, skin ulceration, frequent and massive oral and/or nose bleeding, Thyroid: cT4, every cT with bulky N+, aggressive histotypes (medullary, tall cell, undifferentiated…), Salivary glands: cT3-cT4, every cTN+, aggressive histotypes (salivary duct, adenoid cystic, high grade mucoepidermoid…), Skin of face and neck: squamous cell carcinomas cT3-cT4 and every cTN+, Every G2-G3 soft tissues or bone sarcomas, Thyroid: cT2-cT3, non-bulky and non-critical N+, Skin of face and neck: squamous cell carcinoma cT1-cT2, large basal cell carcinomas, Skin of face and neck: small basal cell carcinomas, Multidisciplinary team meetings -physically or virtually- should remain the place where clinical choices about curative treatments are mainly defined, High-medium priority patients should not be delayed more than 2 months, Definitive (chemo)radiotherapy for oropharyngeal carcinoma regardless of HPV status and for advanced hypopharyngeal or laryngeal carcinoma, Continuation of treatment in the context of a clinical trial, provided patient benefits outweigh risks, with possible adaptation of procedures without affecting patient safety and study conduct, Postoperative (chemo)radiotherapy for non-in-sano resection/positive margins or extracapsular spread of squamous cell carcinomas, sarcomas, or salivary gland tumours of aggressive histology, Definitive radiotherapy of early glottic cancer (cT1-cT2 N0), Symptomatic palliative treatment (e.g. with immune checkpoint inhibitors) in frail patients, In patients on treatment with immune checkpoint inhibitors and having achieved partial/complete response or with clinical benefit and without toxicities, consider switching from a q2-3w schedule to a  q4-6w schedule to reduce medical visits (a telemedicine visit with or without laboratory testing between two treatment cycles is suggested to monitor these patients, who often are frail), Patients on IO showing signs of pneumonitis on CT scans should be tested for COVID-19 before administering steroids, For patients in treatment with intravenous chemotherapy, shift to oral chemotherapy (e.g. Most frequent histologic type in Head and Neck cancer. Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. For more detailed information on the cookies we use, please check our Privacy Policy. 030 - 899 06 65 secretariaat@nvmo.org ESMO Clinical Practice Guidelines: Head and Neck Cancers, Clinical Practice Guidelines – Nasopharyngeal Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Clinical Practice Guidelines – Squamous Cell Carcinoma of the Head and Neck, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, Cancer Patient Management During the COVID-19 Pandemic, COVID-19 and cancer care in the ESMO journals, From ESMO Vision 2020 to ESMO Vision 2025, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Translational Research and Precision Medicine Working Group, Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group. These guidelines on Squamous cell carcinoma of the head and neck and Nasopharyngeal cancer include information on: incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up. Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO-ESO Courses on Medical Oncology for Medical Students, SARS-CoV-2 Vaccination: Special Considerations in Patients with Cancer, ESMO Guidelines: Real World Cases - Live Webinars.